IRS1 and obesity disorder: Lrg1 promotes obesity‐induced hepatosteatosis by enhancing de novo lipogenesis while attenuating fatty acid β‐oxidation and inhibits hepatic insulin signaling through interactions with insulin receptor substrates 1 and 2 [73].